Krebs Biochemicals & Industries Limited (KREBSBIO.BO)
INR 72.4
(1.7%)
INR 72.4
(1.7%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 1.93 Billion INR | -15.35% |
| 2022 | 2.28 Billion INR | 21.42% |
| 2021 | 1.88 Billion INR | 49.8% |
| 2020 | 1.25 Billion INR | 54.7% |
| 2019 | 811.56 Million INR | 5.48% |
| 2018 | 769.36 Million INR | -15.9% |
| 2017 | 914.8 Million INR | 16.29% |
| 2016 | 786.65 Million INR | 159.61% |
| 2015 | 303 Million INR | 99.83% |
| 2014 | 151.63 Million INR | 0.0% |
| 2011 | 794.94 Million INR | -7.15% |
| 2010 | 856.17 Million INR | -0.69% |
| 2009 | 862.13 Million INR | 4.81% |
| 2008 | 822.54 Million INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 FY | 1.93 Billion INR | -15.35% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q4 | 1.93 Billion INR | 0.0% |
| 2023 Q2 | 1.87 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 FY | 2.28 Billion INR | 21.42% |
| 2022 Q2 | 1.73 Billion INR | 0.0% |
| 2022 Q4 | 2.28 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q2 | 1.22 Billion INR | 0.0% |
| 2021 Q4 | 1.88 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 FY | 1.88 Billion INR | 49.8% |
| 2020 FY | 1.25 Billion INR | 54.7% |
| 2020 Q4 | 1.25 Billion INR | 0.0% |
| 2020 Q2 | 816.48 Million INR | 0.0% |
| 2019 Q4 | 811.56 Million INR | 0.0% |
| 2019 Q2 | 499.15 Million INR | 0.0% |
| 2019 FY | 811.56 Million INR | 5.48% |
| 2018 Q4 | 769.36 Million INR | 0.0% |
| 2018 Q2 | 509 Million INR | 0.0% |
| 2018 FY | 769.36 Million INR | -15.9% |
| 2017 Q4 | 512.43 Million INR | 0.0% |
| 2017 Q2 | 512 Million INR | 0.0% |
| 2017 FY | 914.8 Million INR | 16.29% |
| 2016 FY | 786.65 Million INR | 159.61% |
| 2016 Q2 | 790.38 Million INR | 0.0% |
| 2016 Q4 | 426.7 Million INR | 0.0% |
| 2015 FY | 303 Million INR | 99.83% |
| 2015 Q4 | 303 Million INR | 0.0% |
| 2015 Q2 | 653.05 Million INR | 0.0% |
| 2014 FY | 151.63 Million INR | 0.0% |
| 2013 Q3 | 267.54 Million INR | 0.0% |
| 2012 Q2 | 871.7 Million INR | 0.0% |
| 2011 FY | 794.94 Million INR | -7.15% |
| 2011 Q4 | 794.94 Million INR | 0.0% |
| 2010 FY | 856.17 Million INR | -0.69% |
| 2009 FY | 862.13 Million INR | 4.81% |
| 2008 FY | 822.54 Million INR | 0.0% |
| 2008 Q4 | 822.54 Million INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | 50.001% |
| Aurobindo Pharma Limited | 3.69 Billion INR | 47.664% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | 167.997% |
| Granules India Limited | 9.28 Billion INR | 79.186% |
| Indoco Remedies Limited | 6.47 Billion INR | 70.154% |
| Achyut Healthcare Limited | -3.74 Million INR | 51699.6% |
| Ajanta Pharma Limited | -954.9 Million INR | 302.421% |
| Alkem Laboratories Limited | -1.6 Billion INR | 220.102% |
| Alpa Laboratories Limited | 35.36 Million INR | -5365.942% |
| Brooks Laboratories Limited | 49.48 Million INR | -3806.075% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 138.562% |
| Bajaj HealthCare Limited | 3.29 Billion INR | 41.408% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | 266.955% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 85.031% |
| Eris Lifesciences Limited | 13.8 Billion INR | 86.0% |
| FDC Limited | -57.75 Million INR | 3446.933% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 145.106% |
| Gufic Biosciences Limited | 3.19 Billion INR | 39.489% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | 146.542% |
| Ipca Laboratories Limited | 11.41 Billion INR | 83.067% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | 239.066% |
| Lasa Supergenerics Limited | 205.79 Million INR | -839.228% |
| Laurus Labs Limited | 24.38 Billion INR | 92.073% |
| Lupin Limited | 17.19 Billion INR | 88.757% |
| Mankind Pharma Limited | -9.9 Billion INR | 119.509% |
| Medicamen Biotech Limited | 160.31 Million INR | -1105.694% |
| Medico Remedies Limited | 78.67 Million INR | -2356.78% |
| Megasoft Limited | 1.28 Billion INR | -50.357% |
| NATCO Pharma Limited | -5.81 Billion INR | 133.229% |
| Piramal Pharma Limited | 42.27 Billion INR | 95.428% |
| RPG Life Sciences Limited | -364.7 Million INR | 630.003% |
| Sigachi Industries Limited | 859.94 Million INR | -124.772% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 102.667% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | -1233.27% |
| Syncom Formulations (India) Limited | 46.21 Million INR | -4082.816% |
| Unichem Laboratories Limited | 931.91 Million INR | -107.414% |
| Wanbury Limited | 1.1 Billion INR | -74.787% |
| Windlas Biotech Limited | -273.04 Million INR | 807.926% |
| ZIM Laboratories Limited | 983.6 Million INR | -96.514% |
| Zydus Lifesciences Limited | 3.91 Billion INR | 50.59% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | 305.237% |
| Divi's Laboratories Limited | -39.77 Billion INR | 104.86% |
| Hester Biosciences Limited | 2.29 Billion INR | 15.62% |
| Procter & Gamble Health Limited | -2.34 Billion INR | 182.322% |
| Amrutanjan Health Care Limited | -248.79 Million INR | 876.922% |
| Bal Pharma Limited | 1.26 Billion INR | -52.974% |
| Strides Pharma Science Limited | 23.25 Billion INR | 91.689% |
| Venus Remedies Limited | -267.7 Million INR | 822.047% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | 25.996% |
| Nectar Lifesciences Limited | 6.15 Billion INR | 68.608% |
| Shilpa Medicare Limited | 9.06 Billion INR | 78.688% |
| Aarti Drugs Limited | 5.54 Billion INR | 65.163% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | 275.513% |
| Suven Life Sciences Limited | -1.63 Billion INR | 218.388% |
| Ind-Swift Limited | 9.5 Billion INR | 79.672% |
| Valiant Laboratories Limited | -295.03 Million INR | 755.156% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | 31.486% |
| Solara Active Pharma Sciences Limited | 10.02 Billion INR | 80.727% |
| Themis Medicare Limited | 764.96 Million INR | -152.682% |
| Hikal Limited | 7.96 Billion INR | 75.738% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 93.927% |
| Sequent Scientific Limited | 4.17 Billion INR | 53.743% |
| Novartis India Limited | -5.89 Billion INR | 132.811% |
| Wockhardt Limited | 18.27 Billion INR | 89.42% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 92.86% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | 10578.808% |
| Neuland Laboratories Limited | -214.05 Million INR | 1002.989% |
| Morepen Laboratories Limited | -231.17 Million INR | 936.133% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | -1510.244% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | -98.084% |